Burzynski Research Institute IncOOTC BZYR Stock Report

Burzynski Research Institute, Inc. is a biopharmaceutical company. The company is headquartered in Houston, Texas. The company went IPO on 2001-10-15. The chemical compounds are composed of growth-inhibiting peptides, amino acid derivatives, and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. All Phase II clinical trials were for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The firm has not generated any operating revenue since its inception. The firm's clinical trials are conducted at the Burzynski Clinic.